Pure Global
NCT06417801

Prevalence of Emerging Treatment-induced Mutations in Metastatic ER-positive Breast Cancer.

PANGEIA-2: Prevalence of Emerging Treatment-induced Mutations in metastaticER Positive Breast Cancer.
AstraZeneca·ClinicalTrials.govNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Metastatic Breast Cancer
Study type
Observational
Sponsor & location
Primary sponsor
AstraZeneca
Location
São Paulo, Brazil
Timeline & enrollment
Phase
N/A
Start date
Oct 01, 2024
End date
Dec 01, 2024
Enrollment
70 participants
Primary outcome

Prevalence of emerging ESR1 mutations

Summary

Observational study on prevalence of emerging ESR1 mutations in liquid biopsy in two cohorts
 of patients with breast cancer (with and without prior therapies in metastatic setting) in
 comparison with patient's baseline ESR1 mutation status as defined by tissue profiling.

ICD-10 classifications
Malignant neoplasm of breastMalignant neoplasm of breastMalignant neoplasm: Breast, unspecifiedMalignant neoplasm: Central portion of breastMalignant neoplasm: Overlapping lesion of breast
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06417801
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06417801 through Pure Global AI's free database. This phase not specified trial is sponsored by AstraZeneca and is currently Not yet recruiting. The study focuses on Metastatic Breast Cancer. Target enrollment is 70 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.